Sanner launches senior-friendly closure for effervescent packaging
![](/46/pdcnewsitem/04/14/61/Sanner_FOG_27_Verschlussband.jpg)
The warranty band of FOG 27 is easy to remove while the closure remains firmly attached to the tube
The new FOG 27 closure can be opened in about a third of the time — and with 70% less physical effort compared with conventional closures.
Sanner has developed a new closure for effervescent packaging. Participants of a comparative study confirm that the new FOG 27 closure can be opened in about a third of the time — and with 70% less physical effort compared with conventional closures. Food supplement producers gain satisfied customers and accordingly high repurchase rates.
About a quarter of adults consume nutritional supplements such as vitamins or minerals, often sold as effervescent tablets. About half of these consumers are 60 years or older. According to the German Federal Association of Senior Citizens‘ Organizations (BAGSO), more than 90% of senior citizens struggle with opening consumer packaging in general; three quarters criticize the handling properties of opening mechanisms in particular.
Subsequently, good and easy handling of the packaging is especially important. “For producers of food supplements this is a decisive factor,” says Ursula Hahn, product manager at Sanner. “In case of bad experiences with the packaging, repurchase rates decline considerably.” To find a remedy, Sanner has developed the new, user-friendly FOG 27 closure — and let consumers judge in a comprehensive study.
FOG 27 convinces in consumer test
The test, conducted by the market research institutes Quo Vadis and Packaging Intelligence, focused on the way of opening, as well as the time and physical effort required. The quantitative handling test surveyed 120 women (60%) and men (40%) in charge of their respective households, who purchase and consume vitamin, mineral or painkiller tablets two to three times per month.
The most striking result of the test is that 87% of the participants confirmed the intuitive opening. Apart from the easy removal of the warranty band, testers particularly appreciated the painless, single-handed opening. They neither complained about pressure marks on their thumb, nor about aching fingers. As far as opening time is concerned, the new FOG 27 also stands out from conventional closures: participants required approximately a third of the time to open the FOG 27 (9.2 instead of 25.8 seconds). Moreover, the amount of physical effort needed for the first opening is significantly lower: 12 newton instead of 36 newton.
Reliable product protection, higher convenience
In terms of tightness, the FOG 27 is just as reliable as conventional closures: despite the easy opening, full product protection is ensured. “One of the reasons,” Ursula Hahn explains, "is that the FlipTop of the new closure is tightly attached to the tube and can be intuitively closed.” Another advantage: the closure cannot get lost. This way, a small packaging optimization provides significantly higher convenience and customer satisfaction. Thanks to the good handling, around 90% of best-agers would buy the product with the user-friendly FOG 27 closure again.
Together with the Brilliance Tubes from Sanner, which are decorated using in-mold labelling (IML) technology, customers receive an all-in-one solution for highest convenience and attention at point-of-sale. The Brilliance Tubes offer high-quality, photorealistic printing with endless design varieties. The font size can be flexibly adapted to improve readability. Especially expressive motifs attract customers’ attention; sales messages can be conveyed without many words.
Satisfied customers — high repurchase rates
Ursula Hahn is convinced that "who wants to achieve long-term customer loyalty cannot escape this trend.” Whether as single closure or combined with the Brilliance Tube, the FOG 27 provides several solutions in one: “customers receive a user-friendly packaging; and food supplement producers obtain an especially attractive solution, satisfied customers, and higher repurchase rates,” Hahn concludes.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance